• Molecular NamePropericiazine
  • SynonymPericyazine
  • Weight365.501
  • Drugbank_IDDB01608
  • ACS_NO2622-26-6
  • Show 3D model
  • LogP (experiment)3.52
  • LogP (predicted, AB/LogP v2.0)4.13
  • pkaN/A
  • LogD (pH=7, predicted)2.48
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.42
  • LogSw (predicted, AB/LogsW2.0)0.03
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds5
  • TPSA75.8
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyFor use as adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding90.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityIn milder cases of phenothiazine overdosage the patient may be agitated, delirious and confused. Frequently he is lethargic or in a comatose state. Twitching, dystonic movements or convulsions may be present and hypotension, cardiovascular collapse, arrhythmias and hypothermia might be observed.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A